Recent advances and challenges of bispecific antibodies in solid tumors

Experimental Hematology & Oncology

Haiyong Wang¹  Yuze Wu²  Kongming Wu²  Shuangli Zhu²  Ming Yi² 

[1] Beijing Anjianxi Medicinal Technology Co., Ltd., No.2 Cuiwei Road, Haidian District, 100036, Beijing, China;Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China;

关键词: BsAb;    Solid tumor;    EpCAM;    CEA;    PSMA;    EGFR;    HER2;   

DOI  :  10.1186/s40164-021-00250-1

来源: Springer

【 摘 要 】

Cancer immunotherapy has made remarkable progress in the past decade. Bispecific antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody-target cancer immunotherapy, which overwhelmingly focus on T cell recruitment and dual receptors blockade. So far, BsAb drugs have been proved clinically effective and approved for the treatment of hematologic malignancies, but no BsAb have been approved in solid tumors. Numerous designed BsAb drugs for solid tumors are now undergoing evaluation in clinical trials. In this review, we will introduce the formats of bispecific antibodies, and then update the latest preclinical studies and clinical trials in solid tumors of BsAbs targeting EpCAM, CEA, PMSA, ErbB family, and so on. Finally, we discuss the BsAb-related adverse effects and the alternative strategy for future study.

【 授权许可】

CC BY